We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Temozolomide + Vorinostat in Patients With Relapse/Refractory AML

This study has suspended participant recruitment.
(Review)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01550224
First Posted: March 9, 2012
Last Update Posted: August 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Stanford University
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 31, 2019
  Estimated Primary Completion Date: March 31, 2019 (Final data collection date for primary outcome measure)

To Top